Steve Seedhouse
Stock Analyst at Cantor Fitzgerald
(4.43)
# 3,784
Out of 5,182 analysts
22
Total ratings
70%
Success rate
16.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | n/a | $40.90 | - | 4 | Apr 1, 2026 | |
| IRD Opus Genetics | Initiates: Overweight | $15 | $5.75 | +160.87% | 1 | Mar 30, 2026 | |
| SRZN Surrozen | Reiterates: Overweight | $40 | $31.56 | +26.74% | 2 | Mar 24, 2026 | |
| KRRO Korro Bio | Maintains: Overweight | $21 → $22 | $14.39 | +52.88% | 3 | Mar 13, 2026 | |
| HROW Harrow | Maintains: Overweight | $94 → $91 | $41.50 | +119.28% | 2 | Mar 4, 2026 | |
| BLTE Belite Bio | Maintains: Overweight | $200 → $266 | $165.45 | +60.77% | 2 | Mar 3, 2026 | |
| WVE Wave Life Sciences | Maintains: Overweight | $34 → $41 | $7.49 | +447.40% | 2 | Feb 5, 2026 | |
| XNCR Xencor | Maintains: Overweight | $40 → $42 | $13.06 | +221.59% | 2 | Nov 6, 2025 | |
| INVA Innoviva | Maintains: Overweight | $29 → $31 | $24.24 | +27.89% | 2 | Nov 6, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Overweight | $7 | $4.49 | +55.90% | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $3.39 | +1,433.92% | 1 | Jul 11, 2025 |
Apellis Pharmaceuticals
Apr 1, 2026
Downgrades: Neutral
Price Target: n/a
Current: $40.90
Upside: -
Opus Genetics
Mar 30, 2026
Initiates: Overweight
Price Target: $15
Current: $5.75
Upside: +160.87%
Surrozen
Mar 24, 2026
Reiterates: Overweight
Price Target: $40
Current: $31.56
Upside: +26.74%
Korro Bio
Mar 13, 2026
Maintains: Overweight
Price Target: $21 → $22
Current: $14.39
Upside: +52.88%
Harrow
Mar 4, 2026
Maintains: Overweight
Price Target: $94 → $91
Current: $41.50
Upside: +119.28%
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $200 → $266
Current: $165.45
Upside: +60.77%
Wave Life Sciences
Feb 5, 2026
Maintains: Overweight
Price Target: $34 → $41
Current: $7.49
Upside: +447.40%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $40 → $42
Current: $13.06
Upside: +221.59%
Innoviva
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $31
Current: $24.24
Upside: +27.89%
Camp4 Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: $7
Current: $4.49
Upside: +55.90%
Jul 11, 2025
Initiates: Overweight
Price Target: $52
Current: $3.39
Upside: +1,433.92%